Castle Biosciences CSTL Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Castle Biosciences in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Castle Biosciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Castle Biosciences's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Castle Biosciences's business segments — net loss?
- Castle Biosciences (CSTL) reported business segments — net loss of -$14.52M in Q1 2026.
- How has Castle Biosciences's business segments — net loss changed year-over-year?
- Castle Biosciences's business segments — net loss increased by 43.8% year-over-year, from -$25.85M to -$14.52M.
- What is the long-term trend for Castle Biosciences's business segments — net loss?
- Over 3 years (2022 to 2025), Castle Biosciences's business segments — net loss has grown at a -28.9% compound annual growth rate (CAGR), from -$67.14M to -$24.16M.
- What does business segments — net loss mean?
- Indicates the bottom-line financial result of the segment after deducting all associated operating expenses from revenues. A negative value signifies that the segment's costs currently exceed its revenue generation, highlighting the need for operational leverage.